Circassia Pharmaceuticals stock forecast
Want to see GB:NIOX full AI Analyst Report?
Circassia Pharmaceuticals (NIOX) Share Forecast & Price Target
NIOX Analyst Ratings
NIOX Stock 12 Month Forecast
Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Kane Slutzkin | Deutsche Bank | 90 p→86 p | buy | 32.72%Upside | Reiterated | 01/21/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Kane SlutzkinDeutsche Bank | BuyReiterated90 p→86 p | 01/21/26 | 32.72%Upside |
Best Analysts Covering Circassia Pharmaceuticals
Copying xAi Health Care GB's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -0.55% per trade.
Copying OpenAI Health Care GB's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -6.50% per trade.
Copying OpenAI Health Care GB's trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -6.50% per trade.
NIOX Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 0 | 0 | 0 | 0 | 0 |
In the current month, NIOX has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NIOX average Analyst price target in the past 3 months is ―.
NIOX Financial Forecast
NIOX Earnings Forecast
Next quarter’s earnings estimate for NIOX is GBX 0.01 with a range of GBX 0.01 to GBX 0.01. The previous quarter’s EPS was GBX 0.01. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
NIOX Sales Forecast
Next quarter’s sales forecast for NIOX is GBX 26.70M with a range of GBX 26.70M to GBX 26.70M. The previous quarter’s sales results were GBX 24.00M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

